[ad_1]
SHANGHAI • In 2002, Mr. Lu Yong was told that he could only hope to live three more years after being diagnosed with chronic myeloid leukemia
But there were l & # 39; hope.
Glivec, from the Swiss pharmaceutical giant Novartis He could stabilize his condition until he could receive a potentially life-saving bone marrow transplant.
But Glivec then costed 24,000 yuan a bottle in China.
A generic Indian version only cost 2 000 yuan so he started to order But the Indian drug was banned by the Chinese rules and he was arrested in 2013.
Now a movie called Dying To Survive, based on His experience is about to become one of the most lucrative films of China
. Released on July 5, it even passed the first week of Wolf Warrior 2, a commando adventure that took advantage of patriotism to become China's highest-gross
Featuring Xu Zheng, comedian and popular comic actor, as a character inspired by Mr. Lu, the film uses black comedy to lift the heavy subject.
In a rare u-turn, prosecutors in central Hunan province abandoned Mr. Lu's case after thousands of Chinese patients with leukemia signed an open letter demanding his release
M. Lu, who said he never took advantage of the plan, has never been charged. He said in his personal blog
that Chinese censors have rarely given the green light to mass releases on sensitive topics. But the main villain in Dying To Survive is the pharmaceutical industry and the authorities have apparently seen the value of a movie that portrays the government as sensitive about the issue.
The country announced earlier this year that it would raise tariffs on many cancer treatments and the buzz around the film's release coincided with even more change.
million. Lu said, "Since the release of the film, it has become a sensation … Being able to push health care reform is a great thing."
He runs a factory in eastern China that makes gloves and is still waiting for his transplant.
Last Friday, the film earned 2.04 billion yuan ($ 417 million).
Wolf Warrior 2 reported 5.67 billion yuan in 12-week cinema
AGENCY FRANCE-PRESS
[ad_2]
Source link
